New fatty liver drug tested in healthy volunteers – no cure expected
NCT ID NCT07335198
First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 1 time
Summary
This early-stage study tests a single dose of the experimental drug efimosfermin alfa in 30 healthy adults of Chinese, Japanese, and White/European ancestry. The goal is to check safety, how the body processes the drug, and immune reactions. Participants will not receive any treatment for fatty liver disease, as this is a safety study only.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-ALCOHOLIC FATTY LIVER DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
GSK Investigational Site
Auckland, 1010, New Zealand
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could immune cells in fat hold the key to Obesity-Related disease?
- A new MRI technique could see inside the Liver's metabolism without a biopsy
- Can Weight-Loss surgery beat drugs for advanced liver damage?
- Can fatty liver in children lead to serious liver disease? a Long-Term study aims to find out
- Can a scan replace the needle? ultrasound and MRI put to the test against liver biopsy for fatty liver disease
- Can fish oil shrink a fatty liver?